Penpulimab 是一种 IgG1 抗 PD-1 单克隆抗体，具有抗肿瘤活性。

Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities.

Liquid

Penpulimab demonstrates better stability and a lower level of host-cell protein residue compared with IgG4 backbone anti-PD-1 antibodies.
Penpulimab does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC) and induces no remarkable IL-6 and IL-8 release by activated macrophages.
Penpulimab exhibits slower binding off-rate for human PD-1 than Nivolumab (HY-P9903) and Pembrolizumab (HY-P9902).
Penpulimab potentiates T cell activation via PD-1/PD-L1 blockade. has not independently confirmed the accuracy of these methods. They are for reference only.

Penpulimab (5 mg/kg; i.p.; twice a week, 3weeks) inhibits tumor growth in mice. has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MC38-hPD-L1 tumor-bearing B-hPD-1 humanized mouse model

Please store the product under the recommended conditions in the Certificate of Analysis.

[1]. Huang Z, et al. Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events. Front Immunol. 2022 Jun 27;13:924542.
[2]. Yunlong Shan, et al. Anlotinib enhanced penpulimab efficacy through remodeling of tumor vascular architecture and immune microenvironment in hPD-L1/hPD-1 humanized mouse model. Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 2581-2581.